| 1 | BRAF, KIAA1549
|
| Clinical, radiological and molecular characterization of intramedullary astrocytomas
|
| Lebrun L, Meléndez B, Blanchard O, De Nève N, Van Campenhout C, Lelotte J, Balériaux D, Riva M, Brotchi J, Bruneau M, De Witte O, Decaestecker C, D'Haene N, Salmon I
|
| Acta Neuropathol Commun. Aug 8;8(1):128. doi: 10.1186/s40478-020-00962-1. 2020
|
| 2 | BRAF, MTOR, RHEB
|
| An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
|
| Heard JJ, Phung I, Potes MI, Tamanoi F.
|
| BMC Cancer 18(1):69. doi: 10.1186/s12885-017-3938-5.
2018
|
| 3 | BRAF, FZR1
|
| The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.
|
| Wan L, Chen M, Cao J, Dai X, Yin Q, Zhang J, Song SJ, Lu Y, Liu J, Inuzuka H, Katon JM, Berry K, Fung J, Ng C, Liu P, Song MS, Xue L, Bronson RT, Kirschner MW, Cui R, Pandolfi PP, Wei W.
|
| Cancer Discov. Apr;7(4):424-441. doi: 10.1158/2159-8290.CD-16-0647. Epub 2017 Feb 7. 2017
|
| 4 | BRAF, MAP2K1
|
| Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
|
| Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S.
|
| Cancer Cell 26(3):402-13. doi: 10.1016/j.ccr.2014.07.007. Epub 2014 Aug 21.
2014
|
| 5 | BRAF
|
| Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
|
| Matsuse M, Mitsutake N, Tanimura S, Ogi T, Nishihara E, Hirokawa M, Fuziwara CS, Saenko VA, Suzuki K, Miyauchi A, Yamashita S.
|
| Int J Cancer 132(3):738-43. doi: 10.1002/ijc.27709. Epub 2012 Jul 21.
2013
|
| 6 | BRAF
|
| Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues.
|
| Dağlar-Aday A, Toptaş B, Oztürk T, Seyhan F, Saygili N, Eronat AP, Akadam-Teker B, Yilmaz-Aydoğan H, Aksoy F, Oztürk O.
|
| DNA Cell Biol 32(1):13-8. doi: 10.1089/dna.2012.1776. Epub 2012 Nov 16.
2013
|
| 7 | BRAF, MITF, PPARGC1A
|
| Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
|
| Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR.
|
| Cancer Cell 23(3):302-15. doi: 10.1016/j.ccr.2013.02.003. Epub 2013 Mar 7.
2013
|
| 8 | BRAF, NDE1, PAFAH1B1
|
| Spatially dependent dynamic MAPK modulation by the Nde1-Lis1-Brap complex patterns mammalian CNS.
|
| Lanctot AA, Peng CY, Pawlisz AS, Joksimovic M, Feng Y.
|
| Dev Cell 25(3):241-55. doi: 10.1016/j.devcel.2013.04.006.
2013
|
| 9 | BRAF, NF1
|
| Elucidating distinct roles for NF1 in melanomagenesis.
|
| Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K.
|
| Cancer Discov 3(3):338-49. doi: 10.1158/2159-8290.CD-12-0313. Epub 2012 Nov 21.
2013
|
| 10 | BRAF, RNF149
|
| Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF).
|
| Hong SW, Jin DH, Shin JS, Moon JH, Na YS, Jung KA, Kim SM, Kim JC, Kim KP, Hong YS, Lee JL, Choi EK, Lee JS, Kim TW.
|
| J Biol Chem 287(28):24017-25. doi: 10.1074/jbc.M111.319822. Epub 2012 May 24.
2012
|
| 11 | BRAF
|
| Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.
|
| Röring M, Brummer T.
|
| Crit Rev Oncog 17(1):97-121. Review.
2012
|
| 12 | BRAF
|
| Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia.
|
| Langabeer SE, Quinn F, O'Brien D, McElligott AM, Kelly J, Browne PV, Vandenberghe E.
|
| Leuk Res 36(4):483-4. doi: 10.1016/j.leukres.2011.12.015. Epub 2012 Jan 9.
2012
|
| 13 | BRAF
|
| Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.
|
| Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A.
|
| Proc Natl Acad Sci U S A 109(6):E353-9. doi: 10.1073/pnas.1105026109. Epub 2011 Dec 27.
2012
|
| 14 | BRAF, SLC5A1
|
| Stimulation of the Na(+)-coupled glucose transporter SGLT1 by B-RAF.
|
| Pakladok T, Hosseinzadeh Z, Alesutan I, Lang F.
|
| Biochem Biophys Res Commun 427(4):689-93. doi: 10.1016/j.bbrc.2012.09.062. Epub 2012 Sep 23.
2012
|
| 15 | BRAF, KSR1, RAF1
|
| Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
|
| Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, Shaw AS.
|
| Proc Natl Acad Sci U S A 108(15):6067-72. Epub 2011 Mar 25.
2011
|
| 16 | BRAF, DHODH
|
| DHODH modulates transcriptional elongation in the neural crest and melanoma.
|
| White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J, Kaufman C, Chen F, Long HK, Kramer M, Datta S, Neuberg D, Granter S, Young RA, Morrison S, Wheeler GN, Zon LI.
|
| Nature 471(7339):518-22. 2011
|
| 17 | BRAF, SLC9A1
|
| B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
|
| Karki P, Li X, Schrama D, Fliegel L.
|
| J Biol Chem 286(15):13096-105. Epub 2011 Feb 23.
2011
|
| 18 | BRAF
|
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
|
| Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.
|
| Nature 480(7377):387-90. doi: 10.1038/nature10662.
2011
|
| 19 | BRAF, RAF1, RAS
|
| Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF.
|
| Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.
|
| Cell 140(2):209-221.PMID: 20141835 2010
|
| 20 | BRAF, IGFBP7
|
| Role for IGFBP7 in senescence induction by BRAF.
|
| Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR.
|
| Cell 141(5):746-7. No abstract available. PMID: 20510919 2010
|
| 21 | BRAF, IGFBP7
|
| IGFBP7 is not required for B-RAF-induced melanocyte senescence.
|
| Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, Scolyer RA, Mann GJ, Becker JC, Kefford RF, Rizos H.
|
| Cell 141(4):717-27.PMID: 20478260 2010
|
| 22 | BRAF, KIAA1549, RAF1, SRGAP3
|
| Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
|
| Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP.
|
| Oncogene 28(20):2119-23. Epub 2009 Apr 13. 2009
|
| 23 | BRAF, NRAS
|
| Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.
|
| Greene VR, Johnson MM, Grimm EA, Ellerhorst JA.
|
| J Invest Dermatol 129(6):1483-8.PMID: 19037234 2009
|
| 24 | BRAF, IQGAP1
|
| IQGAP1 integrates Ca2+/calmodulin and B-Raf signaling.
|
| Ren JG, Li Z, Sacks DB.
|
| J Biol Chem 283(34):22972-82. Epub 2008 Jun 20.
2008
|
| 25 | HRAS, KRAS, BRAF, CFC2, COSTS, CFC3, MAP2K1, MAP2K2, CFC4, CFC5
|
| Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
| Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, HŸbner CA, Korenke GC, Kšnig R, Kress W, KrŸger G, Meinecke P, MŸcke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M.
|
| Clin Genet 73(1):62-70. Epub 2007 Nov 27. 2008
|
| 26 | MAP2K1, MAP2K2, BRAF, CFC3, CFC4, CFC2
|
| Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
|
| Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O.
|
| Hum Mol Genet 17(3):419-30. Epub 2007 Nov 2. 2008
|
| 27 | BRAF, CFC2, CFC3, CFC4, CFC5, COSTS, HRAS, KRAS, MAP2K1, MAP2K2, NS3
|
| The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
|
| Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y.
|
| Hum Mutat 29(8):992-1006.
2008
|
| 28 | BRAF, CFC2, CFC3, COSTS, HRAS, KRAS, LEOPS, MAP2K1, MAPK1, MTOR, NF1, NFNS, NS1, NS3, NS4, NS5, PTPN11, RAF1, SOS1
|
| Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
|
| Krab LC, Goorden SM, Elgersma Y.
|
| Trends Genet 24(10):498-510. Epub 2008 Sep 4. 2008
|
| 29 | BRAF, MITF
|
| Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
|
| Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R.
|
| PLoS ONE 3(7):e2734.
2008
|
| 30 | BRAF, KIAA1549
|
| Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.
|
| Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP.
|
| Cancer Res 68(21):8673-7.
2008
|
| 31 | BRAF, PLCE1
|
| Identification of BRAF as a new interactor of PLCepsilon1, the protein mutated in nephrotic syndrome type 3.
|
| Chaib H, Hoskins BE, Ashraf S, Goyal M, Wiggins RC, Hildebrandt F.
|
| Am J Physiol Renal Physiol 294(1):F93-9. Epub 2007 Oct 17.PMID: 17942568 2008
|
| 32 | BRAF, CCND1
|
| BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.
|
| Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P.
|
| J Clin Invest 118(5):1739-49.PMID: 18398503 2008
|
| 33 | CFC2, CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, BRAF, COSTS, HRAS
|
| Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
|
| Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillessen-Kaesbach G, Wieczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y.
|
| Am J Med Genet A 143(8):799-807. 2007
|
| 34 | BRAF,IQGAP1
|
| IQGAP1 modulates activation of B-Raf.
|
| Ren JG, Li Z, Sacks DB.
|
| Proc Natl Acad Sci U S A 104(25):10465-9. Epub 2007 Jun 11. 2007
|
| 35 | BRAF,CFC2,CFC3,MAP2K1
|
| Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.
|
| Gripp KW, Lin AE, Nicholson L, Allen W, Cramer A, Jones KL, Kutz W, Peck D, Rebolledo MA, Wheeler PG, Wilson W, Al-Rahawan MM, Stabley DL, Sol-Church K.
|
| Am J Med Genet A 143(13):1472-80. 2007
|
| 36 | BRAF
|
| BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
|
| Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D.
|
| J Clin Endocrinol Metab 92(7):2840-3. Epub 2007 May 8. 2007
|
| 37 | CFC2, BRAF, CFC3, MAP21K1, CFC3, MAP2K2, CFC5, KRAS, COSTS, HRAS
|
| Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
|
| Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, HŽron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, CavŽ H.
|
| J Med Genet 44(12):763-71. Epub 2007 Aug 17. 2007
|
| 38 | BRAF
|
| BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation.
|
| Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S.
|
| Endocrinology 147(12):5699-707. Epub 2006 Sep 7.
2006
|
| 39 | BRAF
|
| BRAF mutation predicts sensitivity to MEK inhibition.
|
| Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N.
|
| Nature 439(7074):358-62. Epub 2005 Nov 6. 2006
|
| 40 | CFC2, BRAF, RAF1, MAP2K1, MAP2K2, CFC3, CFC4
|
| Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
|
| Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA.
|
| Science 311(5765):1287-90. Epub 2006 Jan 26. 2006
|
| 41 | KRAS, BRAF, CFC2
|
| Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
|
| Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y.
|
| Nat Genet 38(3):294-6. Epub 2006 Feb 12. 2006
|
| 42 | BRAF
|
| CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.
|
| Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW.
|
| Nat Genet 38(7):787-93. Epub 2006 Jun 25. 2006
|
| 43 | CFC2, BRAF, CFC3, MAP2K1, CFC4, MAP2K2, COSTS, HRAS
|
| Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype.
|
| Rauen KA.
|
| Am J Med Genet A 140(15):1681-3. No abstract available. 2006
|
| 44 | MC1R, BRAF
|
| MC1R germline variants confer risk for BRAF-mutant melanoma.
|
| Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC.
|
| Science 313(5786):521-2. Epub 2006 Jun 29. 2006
|
| 45 | BRAF, PTEN
|
| Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
|
| Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG.
|
| J Invest Dermatol 126(1):154-60. 2006
|
| 46 | BRAF
|
| The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
|
| Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.
|
| Clin Endocrinol (Oxf) 65(3):364-8. 2006
|
| 47 | AKAP9, BRAF
|
| Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
|
| Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE.
|
| J Clin Invest 115(1):94-101. 2005
|
| 48 | SLC5A8, BRAF
|
| Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas.
|
| Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Dante R, Rousset B.
|
| J Clin Endocrinol Metab 90(5):3028-35. Epub 2005 Feb 1. 2005
|
| 49 | BRAF
|
| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
|
| Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW.
|
| J Clin Endocrinol Metab 90(12):6373-9. Epub 2005 Sep 20. 2005
|
| 50 | BRAF
|
| BRAF polymorphisms and risk of melanocytic neoplasia.
|
| James MR, Roth RB, Shi MM, Kammerer S, Nelson MR, Stark MS, Dumenil T, Montgomery GW, Hayward NK, Martin NG, Braun A, Duffy DL.
|
| J Invest Dermatol 125(6):1252-8. 2005
|
| 51 | RAF1, BRAF, ARAF
|
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
|
| Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project.
|
| Cell 116(6):855-67. 2004
|
| 52 | BRAF
|
| Absence of BRAF mutations in UV-protected mucosal melanomas.
|
| Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, Lessin SR, Weber BL.
|
| J Med Genet 41(4):270-2. 2004
|
| 53 | BRAF, ARAF, RAF1
|
| Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
|
| Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P.
|
| Carcinogenesis 25(4):527-33. Epub 2003 Dec 19. 2004
|
| 54 | BRAF
|
| BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
|
| Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F.
|
| J Clin Endocrinol Metab 89(5):2414-20. 2004
|
| 55 | BRAF, ICMT, KRAS
|
| Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.
|
| Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG.
|
| J Clin Invest 113(4):539-50.
2004
|
| 56 | BRAF
|
| High frequency of BRAF mutations in nevi.
|
| Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS.
|
| Nat Genet 33(1):19-20. 2003
|
| 57 | BRAF
|
| BRAF mutation in papillary thyroid carcinoma.
|
| Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D.
|
| J Natl Cancer Inst 95(8):625-7. 2003
|
| 58 | BRAF
|
| BRAF as a melanoma susceptibility candidate gene?
|
| Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B; French Herediatary Melanoma Study Group.
|
| Cancer Res 63(12):3061-5. 2003
|
| 59 | BRAF
|
| BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
|
| Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M.
|
| Oncogene 22(29):4578-80. 2003
|
| 60 | BRAF
|
| BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.
|
| Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN.
|
| Cancer Res 63(17):5209-12. 2003
|
| 61 | BRAF
|
| BRAF and KRAS mutations in stomach cancer.
|
| Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY, Yoo NJ.
|
| Oncogene 22(44):6942-5. 2003
|
| 62 | BRAF
|
| Mutations of the BRAF gene in benign and malignant melanocytic lesions.
|
| Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A, Mentzel T, Hugel H, Hantschke M, Schmid-Wendtner MH, Kutzner H, Sander CA.
|
| J Invest Dermatol 121(5):1160-2. 2003
|
| 63 | BRAF
|
| Mutations of the BRAF gene in human cancer.
|
| Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA.
|
| Nature 417(6892):949-54. 2002
|
| 64 | BRAF, KRAS
|
| Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
|
| Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE.
|
| Nature 418(6901):934. 2002
|
| 65 | BRAF
|
| Missense mutations of the BRAF gene in human lung adenocarcinoma.
|
| Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M.
|
| Cancer Res 62(23):7001-3. 2002
|
| 66 | BRAF, TRIM24, PML
|
| A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.
|
| Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, Kalantry S, Freedman LP, Pandolfi PP.
|
| Nat Genet 23(3):287-95. 1999
|
| 67 | BRAFPS1, BRAF
|
| B-raf and a B-raf pseudogene are located on 7q in man.
|
| Sithanandam G, et al.
|
| Oncogene 7 : 795-799. 1992
|
| 68 | BRAF
|
| 95-kilodalton B-Raf serine/threonine kinase: identification of the protein and its major autophosphorylation site.
|
| Stephens RM, Sithanandam G, Copeland TD, Kaplan DR, Rapp UR, Morrison DK.
|
| Mol Cell Biol 12(9):3733-42.
1992
|